magnolol has been researched along with Cirrhosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, G; Gao, J; Jiang, M; Li, SY; Lu, YJ; Niu, L; Shen, FK; Xie, Y; Xu, YY; Yang, W; Zu, XW | 1 |
1 other study(ies) available for magnolol and Cirrhosis
| Article | Year |
|---|---|
Magnolol alleviates pulmonary fibrosis inchronic obstructive pulmonary disease by targeting transient receptor potential vanilloid 4-ankyrin repeat domain.
Topics: Ankyrin Repeat; Antineoplastic Agents; Fibrosis; Humans; Molecular Docking Simulation; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; TRPV Cation Channels | 2023 |